Crystal Structure of Human Estrogen-related Receptor α in Complex with a Synthetic Inverse Agonist Reveals Its Novel Molecular Mechanism

• Published in: The Journal of biological chemistry 2007-08, Vol.282 (32), p.23231-23239
• Main Authors: Kallen, Joerg, Lattmann, Rene, Beerli, Rene, Blechschmidt, Anke, Blommers, Marcel J.J., Geiser, Martin, Ottl, Johannes, Schlaeppi, Jean-Marc, Strauss, Andre, Fournier, Brigitte
• Format: Article
• Language: English
• Subjects: Crystallography, X-Ray; Drug Design; ERRalpha Estrogen-Related Receptor; Estrogen Receptor alpha - chemistry; Humans; Kinetics; Ligands; Magnetic Resonance Spectroscopy; Models, Chemical; Models, Molecular; Molecular Conformation; Nitrogen - chemistry; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Receptors, Estrogen - chemistry
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.M703337200

Inverse agonists of the constitutively active human estrogen-related receptorα (ERRα, NR3B1) are of potential interest for several disease indications (e.g. breast cancer, metabolic diseases, or osteoporosis). ERRα is constitutively active, because its ligand binding pocket (LBP) is practically filled with side chains (in particular with Phe328, which is replaced by Ala in ERRβ and ERRγ). We present here the crystal structure of the ligand binding domain of ERRα (containing the mutation C325S) in complex with the inverse agonist cyclohexylmethyl-(1-p-tolyl-1H-indol-3-ylmethyl)-amine (compound 1a), to a resolution of 2.3Å. The structure reveals the dramatic multiple conformational changes in the LBP, which create the necessary space for the ligand. As a consequence of the new side chain conformation of Phe328 (on helix H3), Phe510(H12) has to move away, and thus the activation helix H12 is displaced from its agonist position. This is a novel mechanism of H12 inactivation, different from ERRγ, estrogen receptor (ER) α, and ERβ. H12 binds (with a surprising binding mode) in the coactivator groove of its ligand binding domain, at a similar place as a coactivator peptide. This is in contrast to ERRγ but resembles the situation for ERα (raloxifene or 4-hydroxytamoxifen complexes). Our results explain the novel molecular mechanism of an inverse agonist for ERRα and provide the basis for rational drug design to obtain isotype-specific inverse agonists of this potential new drug target. Despite a practically filled LBP, the finding that a suitable ligand can induce an opening of the cavity also has broad implications for other orphan nuclear hormone receptors (e.g. the NGFI-B subfamily).